Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission

Phase 2

Completed

• Conditions: Leukemia; Leukemia, Myelocytic, Acute; Blood and Marrow Transplant (BMT)

• Registration Number: NCT00186381
• Lead Sponsor: Stanford University

Brief Summary

Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.

Detailed Description

To use high dose chemotherapy with autologous stem cell rescue to try to increase the chance of long term control and cure of the disease.

Study Timeline

• Study Start: 1995-11
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Primary Completion: 2007-03
• Study Completion: 2007-03
• Status Verified: 2010-07
• Last Update Submitted: 2010-07-23
• Last Update Posted: 2010-07-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• must be in remission

• adequate organ function

Exclusion Criteria

• prior MDS

• active infection
• liver disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Disease free survival (DFS)

Secondary Outcome Measures

Name	Time	Method
Transplant related mortality (TRM)
Toxicity
Adequacy of cell collections
Engraftment kinetics

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States